The political issues circling the FDA this year could potentially ripple into biopharma on a scale that's never been seen before. All eyes are on the FDA's response to recent court rulings around the abortion pill mifepristone — and the potential effects on other approvals that might be questioned. What does the future look like, exactly? Join Endpoints' Senior Editor Zachary Brennan in an expert panel to unpack what may come next. We'll also touch on how the FDA is looking for new ways to spur more rare disease drug development with a fireside chat.2:00 - 2:25pm ET (14:00 - 14:25 local time)Fireside chat with Zachary BrennanA one-on-one conversation with Zachary Brennan, Senior Editor at Endpoints, and an industry leader discussing issues at the forefront of rare disease drug development.
2:30 - 3:30pm ET (14:30 - 15:30 local time)Ripple effect: FDA & the abortion drug court sagaWhat can biopharma companies expect from the recent court rulings around the abortion pill mifepristone and FDA's reaction?David S. CohenDavid S. CohenProfessor of LawDrexel University Kline School of LawClick here to find additional details and registration information.
